14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
WABC vs NEWTI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Westamerica Bancorporation (WABC) is the stronger overall head-to-head candidate over NewtekOne, Inc. 8.00% Fixed Rate Senior Notes due 2028 (NEWTI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WABC carries a Unified Composite Score of 58.4/100 (HOLD) at $58.27 (11.8x Forward P/E, 60.6% operating margin), whereas NEWTI carries 51.8/100 (HOLD) at $25.24 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WABC vs NEWTI. Trailing 12-month operating profitability (WABC 60.6% vs NEWTI 0.0%) and valuation multiples (WABC 11.8x vs NEWTI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Other value chain with $426.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ WABC vs NEWTI Key Questions & Quantitative Answers
As of Nov 20, 2026, Westamerica Bancorporation (WABC) is the stronger overall head-to-head candidate over NewtekOne, Inc. 8.00% Fixed Rate Senior Notes due 2028 (NEWTI) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WABC carries a Unified Composite Score of 58.4/100 (HOLD) at $58.27 (11.8x Forward P/E, 60.6% operating margin), whereas NEWTI carries 51.8/100 (HOLD) at $25.24 (N/M Forward P/E, 0.0% operating margin). Technically, WABC sits in a Neutral phase (RSI 38.9, UNCLASSIFIED options structure) and NEWTI sits in a Neutral phase (RSI 51.2, UNCLASSIFIED options structure).
WABC leads the Growth & Scale pillar: WABC posts +0.5% YoY revenue growth and +9.3% YoY earnings growth on $253M TTM revenue (100.0% gross margin, 60.6% operating margin), compared with NEWTI at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, WABC generates $253M in USD-normalized revenue versus N/A for NEWTI. In operating R&D and SG&A reinvestment, WABC deploys 39.4% of Rev ($99M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NEWTI.
WABC screens cheaper on headline valuation multiples. WABC trades at 11.8x Forward P/E, 12.5x Trailing P/E, 4.62x PEG, and 5.3x EV/Revenue (unreported cash flow margin), whereas NEWTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WABC (12.9% ROE) versus NEWTI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, WABC carries 24.8% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 15% Vol realized risk). By comparison, NEWTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.04β · 6% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.